Clinical ResultsImpressive early results for BEAM-302 show a promising effect in correcting the disease-causing PiZ mutation in patients with alpha-1 antitrypsin deficiency (AATD).
Safety And EfficacyNo serious adverse events or dose-limiting toxicities were observed, reinforcing the safety and efficacy profile seen in earlier cohorts.
ValuationBeam's valuation is considered attractive following a recent $500 million equity raise, with limited near-term dilution risk.